Nuveen’s Ovid Therapeutics OVID Stock Holding History

Nuveen’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Buy	+893,254	New	+$2.3M	﹤0.01%	2483
2025 Q2	–	Sell	-119,113	Closed	-$37.2K	–	3371
2025 Q1	$37.2K	Hold	119,113	–	–	﹤0.01%	3270
2024 Q4	$111K	Hold	119,113	–	–	﹤0.01%	3279
2024 Q3	$141K	Hold	119,113	–	–	﹤0.01%	3279
2024 Q2	$91.6K	Hold	119,113	–	–	﹤0.01%	3310
2024 Q1	$363K	Buy	119,113 +5,028	+4%	+$16.8K	﹤0.01%	3057
2023 Q4	$367K	Hold	114,085	–	–	﹤0.01%	3100
2023 Q3	$438K	Hold	114,085	–	–	﹤0.01%	2887
2023 Q2	$374K	Buy	+114,085	New	+$387K	﹤0.01%	2984
2021 Q2	–	Sell	-170,026	Closed	-$683K	–	3492
2021 Q1	$683K	Sell	170,026 -5,553	-3%	-$18.4K	﹤0.01%	3014
2020 Q4	$1.17M	Buy	175,579 +4,897	+3%	+$22.8K	﹤0.01%	2748
2020 Q3	$980K	Sell	170,682 -32,593	-16%	-$218K	﹤0.01%	2704
2020 Q2	$1.5M	Buy	+203,275	New	+$951K	﹤0.01%	2456

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nuveen's OVID Position: Q2 2026 in Review

Nuveen opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 893,254 shares worth $2.4M. The stake represents ﹤0.01% of the portfolio and ranks #2483 among its holdings. This is a return to the name: Nuveen previously reported a position in OVID as recently as Q1 2025.

Nuveen first reported a position in OVID in Q2 2020 and has held it in 13 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Nuveen held 893,254 shares of Ovid Therapeutics worth $2.4M as of Q2 2026.
Ovid Therapeutics was a new Nuveen position in Q2 2026.
Ovid Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2483 holding.
Nuveen first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 13 quarters since.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.